Compare Quest Diagnostics Inc (DGX) vs SkyWest Inc (SKYW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs SkyWest Inc — how do they compare? Quest Diagnostics Inc trades at $237.51 (market cap $26.21B), while SkyWest Inc trades at $107.89 (market cap $4.19B). The key difference: Quest Diagnostics Inc is far larger — about 6.3× SkyWest Inc's market cap, and Quest Diagnostics Inc pays a 1.45% dividend while SkyWest Inc pays none. Which is the better fit depends on your goals.
| DGX | SKYW | |
|---|---|---|
Market Cap | $26.21B | $4.19B |
Sector | Health | Technology |
52-Week High | $238.50 | $123.72 |
52-Week Low | $173.49 | $78.40 |
Enterprise Value | $31.97B | $5.97B |
Dividend Yield | 1.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.99, up 0.15% on the day, near its 52-week high. The stock shows strong momentum with consecutive earnings beats in 2026, including Q2 EPS of $3.12 versus $2.82 expected. Revenue growth accelerated to $11.04 billion in 2025, with net income margin at 9.19%. Technical indicators signal a bullish trend, while analyst consensus is a $249.50 price target. Recent news highlights AI integration and raised 2026 outlook amid robust testing demand.
The outlook for DGX is positive, driven by earnings momentum, strategic partnerships, and healthcare demand. Investment opportunity lies in sustained growth and dividend yield, but risks include margin pressure from lower-margin deals and high debt levels. Valuation at a P/E of 25.21 requires continued execution to justify upside.
SkyWest (SKYW) trades at $107.57, down 0.09% on the day, with a bullish technical signal from moving averages and neutral oscillators. The stock shows solid fundamentals with a P/E of 10.72 and ROE of 15.34%, though Q2 2026 earnings missed estimates. Recent news highlights executive stock sales and a 7.7% post-earnings rally despite misses, supported by fleet expansion and buybacks.
Outlook remains positive with a consensus price target of $109.33 and 56% buy ratings, but risks include fuel cost pressures and mixed earnings performance. The stock offers value appeal with reasonable valuation metrics, yet investor caution is warranted due to insider selling and competitive industry dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About SkyWest Inc
SkyWest, Inc. is a major North American regional airline company, operating primarily through its subsidiary, SkyWest Airlines. The company provides regional airline service to various large airlines under contract, including United Airlines (as United Express), Delta Air Lines (as Delta Connection), American Airlines (as American Eagle), and Alaska Airlines (as Alaska SkyWest). SKYW's primary business is providing essential flight services, connecting smaller cities to major airline hubs across the United States.
Read more on SKYW →
